Nkarta Inc. (NKTX)
Market Open
8 Dec, 17:40
NASDAQ (NGS) NASDAQ (NGS) Primary $
1. 81
+0.01
+0.83%
$
129.98M Market Cap
- P/E Ratio
0% Div Yield
229,701 Volume
-2.1 Eps
$ 1.8
Previous Close Day Range
1.78 1.85
Year Range
1.31 2.74
Want to track NKTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Nkarta: Finally An Attractive Valuation
Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology. The company's off-the-shelf availability and superior safety profile make it an attractive option for patients, providers, and payers. Nkarta is targeting large markets, such as lupus nephritis and non-Hodgkin lymphoma, with the potential to produce blockbuster therapies.
Seekingalpha | 1 year ago
2025 © Marketlog. All Rights Reserved.
